HK Stock MarketDetailed Quotes

01498 PURAPHARM

Watchlist
  • 0.610
  • 0.0000.00%
Not Open Dec 5 16:08 CST
241.50MMarket Cap-2772P/E (TTM)

About PURAPHARM Company

The Group is a Hong Kong Chinese medicine company leading the concentrated Chinese medicine formula granule market. It is engaged in R&D, production, marketing and sales of concentrated Chinese medicine formula granule products under its “Nongbenfang” brand. The Group is one of only five overseas enterprises in China that have obtained approval from the Drug Administration to manufacture and sell concentrated Chinese medicine formula granular products in China. Furthermore, the Group is a national standard laboratory certified by CNAS according to ISO 17025, and the Group's test reports have been recognized by more than 70 countries around the world. Since 2004, the Group has been supplying concentrated Chinese medicine formula granular products to most hospitals and traditional Chinese medicine clinics in Hong Kong. Currently, the Group has secured its leading position in the Hong Kong concentrated Chinese medicine formula granular products market. It is the largest supplier, and is also a leading chain of Chinese medicine clinics in Hong Kong. Since its establishment in 1998, the Group has been committed to the modernization and internationalization of traditional Chinese medicine, and has partnered with many internationally renowned scholars and scientific research institutions to establish its position as a technological pioneer in the Chinese medicine market. Through continuous innovation, the Group has been hailed as a leader in the industry in research and development, production, marketing and sales of traditional Chinese medicines, quality control, and basic scientific research. The Group has established its own traditional Chinese medicine research and production base in Nanning, Guangxi, China. The production facilities not only meet national GMP standards, but also meet the Australian Drug Administration TGA standards, which are among the strictest international standards and certifications, and the PIC/S pharmaceutical standards of the International Pharmaceutical Inspection Organization. The Group is also the only manufacturer of concentrated Chinese medicine formula granular products certified and approved by the US Pharmacopeia USP. The Group's own national standard laboratory has obtained CNAS certification according to ISO 17025. This is an international multilateral mutual certification system, making the Group one of the most advanced traditional Chinese medicine research and production facilities in Asia. With advanced development concepts and production technology, a series of traditional Chinese medicine retail products developed by the Group, such as Ganoderma lucidum, Angelica, Yikangsu, and Uffanong, are popular in Hong Kong and overseas markets.

Company Profile

Symbol01498
Company NamePURAPHARM
ISINKYG7306Y1044
Listing DateJul 8, 2015
Issue Price5.98
Shares Offered71.13M share(s)
FoundedDec 2, 2011
Registered AddressCayman Islands
Chairmanyuling chen
Secretarychaoman chen
Audit InstitutionHong Kong Lixin Dehao Certified Public Accountants Limited
Company CategoryOther
Registered OfficeP.O. Box 31119 Grand Pavilion Hibiscus Way, 802 West Bay Road Grand Cayman KY1-1205, Cayman Islands
Head Office and Principal Place of BusinessRoom 201-207, 2nd floor, Radio Centre, Phase 1, Hong Kong Science Park, Tai Po, New Territories, Hong Kong
Fiscal Year Ends12-31
Employees525
MarketHong Kong motherboard
Phone(852) 2840-1840
Fax(852) 2840-0778
Emailinfo@purapharm.com
Business Peilinong Benfang Co., Ltd. (former name: Peili Holdings Co., Ltd.) is an investment holding company mainly engaged in the business of concentrated Chinese medicine formula granular products. The company operates through five business segments. The China Traditional Chinese Medicine Formula Granule Division is engaged in the production and sale of concentrated traditional Chinese medicine formula granule products in mainland China. The Hong Kong Chinese Medicine Formula Granule Division is mainly engaged in the sales business of concentrated Chinese medicine formula granule products in Hong Kong, China, excluding sales through its own clinics. The Traditional Chinese Medicine Health Products Division is mainly engaged in the production and sale of health products in countries and regions such as Hong Kong and mainland China. The clinic division mainly provides outpatient services of traditional Chinese medicine and sells concentrated Chinese medicine formula granular products through its own clinics. The cultivation division is mainly engaged in the cultivation and trading of Chinese herbal medicines, as well as the production and sale of Chinese medicine tablets.

Company Executives

  • Name
  • Position
  • Salary
  • yuling chen
  • Presidencies, CEO, Executive Director, Chairman of the Nomination Committee, Authorized Representative
  • 6.21M
  • qihui wen
  • Executive Director
  • 3.51M
  • guoqiang liang
  • Non-executive Directors
  • 109.00K
  • guohua he
  • Independent Non-Executive Director, Chairman of the Audit Committee, Remuneration Committee Members, Nomination Committee Members
  • 200.00K
  • nianjian liang
  • Independent Non-Executive Director, Remuneration Committee Chairman, Audit Committee Members
  • 200.00K
  • lizhi xu
  • Independent Non-Executive Director, Remuneration Committee Members, Nomination Committee Members, Audit Committee Members
  • 200.00K
  • yuzhen he
  • Sales Manager
  • --
  • gang shi
  • VP, Chief Representative of Beijing Representative Office
  • --
  • chaoman chen
  • Authorized Representative, Company Secretary
  • --
  • benwenzhe fan
  • CEO of Peili Japan Co., Ltd.
  • 1.25M
Heat List
HK
Overall
Symbol
Latest Price
% Chg

No Data